November 22, 2019 8:19am

News: Roche has again extended the deadline for its tender offer for Spark Therapeutics (ONCE), as U.S. and British anti-trust authorities need more time to review the deal. The offer, which was originally due to expire on Nov. 25, has now been extended to December 10th. All terms and conditions of the offer remain the same, with 14.8% of the shares being tendered to date.

Friday’s pre-open indications: SKIM/SELL – ALNY, BLFS and IONS; BUY – RENE.L and BMRN

Confidence perceived is not always value achieved

 

Skim if you can trim, buy if it will fly and sell if compelled!

 

Dow futures are UP +0.18% (+50 points), S&P futures are UP +0.18% (+6 points) and NASDAQ futures are UP +0.27% (+22 points)

 

U.S. stock index futures were slightly higher, following three straight days of market losses;

European stocks traded in positive territory despite mixed signals over the status of U.S.-China trade discussions as the pan-European Stoxx 600 pared early gains to trade +0.4% higher by mid-morning;

Asia Pacific stocks were mixed amid U.S.-China trade confusion.

 

Data Docket: manufacturing Purchasing Managers’ Index (PMI) and service-sector PMI figures for November will be released at around 9:45 a.m. ET. Consumer sentiment for November and the latest Kansas City Fed Survey will follow slightly later in the session.

 

Henry’omics:

Last night, the sector got clipped to close down in tandem with the markets after a week of 2 positive and 2 negative closes … which equals what (next) – a negative or positive close?

This week so far, the IBB has risen +2.26% and the XBI has risen +2.86% - time for a shake up or down?

The roller coaster is still selling available seats … although the spinning teacups are a cheaper ride.

 

Thursday night’s newsletter heading: “two out of four closes were negative this week.”

  • The NASDAQ closed DOWN -20.52 points (-0.24%);
  • The IBB closed up +0.30% while the XBI closed up +0.16%
  • The range of the 19 upside was +0.10% (FATE) to +9.35% (SLDB) while the 21 downside ranged from -0.05% (RGNX) to -11.91% (CRSP); 
  • 6 out of the 19 upside had higher than the 3 month average volume;
  • 12 out of the 21 downside had higher than the 3 month average volume;

Review the context of Q4’s market – so far:

  • November has registered 7 positive and 8 negative close;
  • October registered 10 positive, 1 neutral and 14 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Friday’s pre-open indications: SKIM/SELL – ALNY, BLFS and IONS; BUY – RENE.L and BMRN

Thursday’s pre-open indications: 4 HITs - SKIM/SELL – ALNY (+$2.99) and IONS (+$0.69); BUY – RENE.L (+$1.50) and NTLA (+$0.16)

Wednesday’s pre-open prognosis: 1 HIT - SELL – CRSP (-$1.04) and 3 MISS - ALNY (+$10.28), GBT (+$0.38)  and RENE.L (+!.50)

Tuesday’s pre-open prognosis: SELL into strength and news: CLBS, CRSP (a “gut” feel an offering was coming), RENE.L SGMO, STML and ALNY – depending on entry pricing

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.